Pediatric epilepsy syndromes

Neurologist

Volumn 16, Issue 4, 2010, Pages 223-237

  Muthugovindan, Deivasumathy ^a   Hartman, Adam L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

diagnosis; epilepsy syndromes; management; pediatric epilepsy

Indexed keywords

BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; CORTICOSTEROID; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUNITRAZEPAM; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PARALDEHYDE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; ANTICONVULSIVE AGENT;

ATTENTION DISTURBANCE; BENIGN CHILDHOOD EPILEPSY; BENIGN CHILDHOOD OCCIPITAL EPILEPSY; BENIGN FAMILIAL NEONATAL CONVUSION; BENIGN FAMILIAL NEONATAL INFANTILE SEIZURE; BENIGN IDIOPATHIC NEONATAL SEIZURE; BENIGN MYOCLONIC EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRAVET SYNDROME; DRUG MEGADOSE; EARLY INFANTILE EPILEPTIC ENCEPHALOPATHY; EARLY MYOCLONIC ENCEPHALOPATHY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; GENE MUTATION; HEMISPHERECTOMY; HUMAN; INFANTILE SPASM; JUVENILE MYOCLONIC EPILEPSY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS EPILEPSY; ONSET AGE; PALLIATIVE THERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RAMUSSEN SYNDROME; REVIEW; ROLANDIC EPILEPSY; SEIZURE; SIDE EFFECT; VAGUS NERVE STIMULATION; WEIGHT GAIN; WEST SYNDROME; CHILD; CLASSIFICATION; EPILEPSY; PATHOPHYSIOLOGY; SYNDROME;

AGE OF ONSET; ANTICONVULSANTS; CHILD; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; PROGNOSIS; SYNDROME;

EID: 77954913416     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181d9d6b7     Document Type: Review

References (161)

1. Engel J Jr, International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001;42:796-803.
2. Dehan M, Quillerou D, Navelet Y, et al. [Convulsions in the fifth day of life: a new syndrome?] Arch Fr Pediatr. 1977;34:730-742. (Pubitemid 8195720)
3. Pryor DS, Don N, Macourt DC. Fifth day fits: a syndrome of neonatal convulsions. Arch Dis Child. 1981;56:753-758.
4. Plouin P. Benign neonatal convulsions (familial and nonfamilial). In: Roger J, Dravet C, Bureau M, et al, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey; 1985:2-11.
5. Miles DK, Holmes GL. Benign neonatal seizures. J Clin Neurophysiol. 1990;7:369-379.
6. Guerra MP, Wilson GA, Boylan GB, et al. An unusual presentation of fifth-day fits in the newborn. Pediatr Neurol. 2002;26:398-401.
7. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18:25-29. (Pubitemid 28027874)
8. Lee WL, Biervert C, Hallmann K, et al. A KCNQ2 splice site mutation causing benign neonatal convulsions in a Scottish family. Neuropediatrics. 2000;31:9-12.
9. Sugiura Y, Nakatsu F, Hiroyasu K, et al. Lack of potassium current in W309R mutant KCNQ3 channel causing benign familial neonatal convulsions (BFNC). Epilepsy Res. 2009;84:82-85.
10. Hirsch E, Velez A, Shellal F, et al. Electroclinical sign of benign neonatal familial convulsions. Ann Neurol. 1993;34:835-841.
11. Kaplan RE, Lacey DJ. Benign familial neonatal-infantile seizures. Am JMed Genet. 1983;16:595-599.
12. Berkovic SF, Heron SE, Giordano L, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol. 2004;55:550-557.
13. Heron SE, Crossland KM, Andermann E, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet. 2002;360:851-852.
14. Herlenius E, Heron SE, Grinton BE, et al. SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia. 2007;48:1138-1142.
15. Ronen GM, Rosales TO, Connolly M, et al. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology. 1993;43: 1355-1360.
16. Heron SE, Cox K, Grinton BE, et al. Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures. J Med Genet. 2007;44:791-796.
17. Singh NA, Otto JF, Dahle EJ, et al. Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J Physiol. 2008; 586:3405-3423.
18. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepi-leptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83:1-43.
19. Ohtahara S, Yamatogi Y, Ohtsuka Y. Prognosis of the Lennox syndrome-long-term clinical and EEG follow-up study, especially with special reference to relationship with the West syndrome. Folia Psychiatr Neurol Jpn. 1976;30:275-287.
20. Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol. 2003;20:398-407.
21. Miller SP, Dilenge ME, Meagher-Villemure K, et al. Infantile epileptic encephalopathy (Ohtahara syndrome) and migrational disorder. Pediatr Neurol. 1998;19:50-54.
22. Williams AN, Gray RG, Poulton K, et al. A case of Ohtahara syndrome with cytochrome oxidase deficiency. Dev Med Child Neurol. 1998;40:568-570.
23. Kato M, Saitoh S, Kamei A, et al. A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet. 2007;81: 361-366.
24. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalop-athy. Nat Genet. 2008;40:782-788.
25. Yamatogi Y, Ohtahara S. Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases. Brain Dev. 2002;24:13-23.
26. Takusa Y, Ito M, Kobayashi A, et al. [Effect of the ketogenic diet for West syndrome into which early infantile epileptic encephalopathy with suppression-burst was evolved]. No To Hattatsu. 1995;27:383-387.
27. Dulac O. Epileptic encephalopathy. Epilepsia. 2001;42(suppl 3):23-26.
28. Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalop-athy. Epilepsy Res. 2006;70(suppl 1):S58-S67.
29. Komaki H, Sugai K, Maehara T, et al. Surgical treatment of early-infantile epileptic encephalopathy with suppression-bursts associated with focal cortical dysplasia. Brain Dev. 2001;23:727-731.
30. Donat JF. The age-dependent epileptic encephalopathies. J Child Neurol. 1992;7:7-21.
31. Aicardi J; Goutieres F. [Neonatal myoclonic encephalopathy (author's transl)]. Rev Electroencephalogr Neurophysiol Clin. 1978;8:99-101.
32. Djukic A, Lado FA, Shinnar S, et al. Are early myoclonic encephalopathy (EME) and the Ohtahara syndrome (EIEE) independent of each other? Epilepsy Res. 2006;70(suppl 1):S68-S76.
33. Dalla Bernardina B, Dulac O, Fejerman N, et al. Early myoclonic epileptic encephalopathy (E.M.E.E.). Eur J Pediatr. 1983;140:248-252.
34. Murakami N, Ohtsuka Y Ohtahara S. Early infantile epileptic syndromes with suppression-bursts: early myoclonic encephalopathy vs. Ohtahara syndrome. Jpn J Psychiatry Neurol. 1993;47:197-200.
35. Wirrell E, Farrell K, Whiting S. The epileptic encephalopathies of infancy and childhood. Can J Neurol Sci. 2005;32:409-418.
36. Frost JD Jr, Hrachovy RA. Pathogenesis of infantile spasms: a model based on developmental desynchronization. J Clin Neurophysiol. 2005;22:25-36.
37. Dulac O, Feingold J, Plouin P, et al. Genetic predisposition to West syndrome. Epilepsia. 1993;34:732-737.
38. Sugai K, Fukuyama Y, Yasuda K, et al. Clinical and pedigree study on familial cases of West syndrome in Japan. Brain Dev. 2001;23:558-564.
39. Stromme P, Mangelsdorf ME, Scheffer IE, et al. Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Brain Dev. 2002;24:266-268.
40. Kato M, Das S, Petras K, et al. Polyalanine expansion of ARX associated with cryptogenic West syndrome. Neurology. 2003;61:267-276.
41. Guzzetta F. Cognitive and behavioral outcome in West syndrome. Epilepsia. 2006;47(suppl 2):49-52.
42. Cowan LD. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev. 2002;8:171-181.
43. Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev. 2001;23:688-691.
44. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia. 2004;45:1416-1428.
45. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62:1668-1681.
46. Mikati MA, Lepejian GA, Holmes GL. Medical treatment of patients with infantile spasms. Clin Neuropharmacol. 2002;25:61-70.
47. Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186-1191.
48. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14:71-74.
49. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2008;8:CD001770.
50. Kossoff EH, Hedderick EF, Turner Z, et al. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia. 2008;49:1504-1509.
51. Overby PJ, Kossoff EH. Treatment of infantile spasms. Curr Treat Options Neurol. 2006;8:457-464.
52. Dravet C, Bureau M, Genton P. Benign myoclonic epilepsy of infancy: electroclinical symptomatology and differential diagnosis from the other types of generalized epilepsy of infancy. Epilepsy Res Suppl. 1992;6:131-135.
53. Auvin S, Pandit F, De Bellecize J, et al. Benign myoclonic epilepsy in infants: electroclinical features and long-term follow-up of 34 patients. Epilepsia. 2006;47:387-393.
54. Dravet C, Bureau M. Benign myoclonic epilepsy in infancy. Adv Neurol. 2005;95:127-137.
55. Darra F, Fiorini E, Zoccante L, et al. Benign myoclonic epilepsy in infancy (BMEI): a longitudinal electroclinical study of 22 cases. Epilepsia. 2006; 47(suppl 5):31-35.
56. Fenichel GM. Clinical Pediatric Neurology. A Signs and Symptoms Approach. Philadelphia, PA: Saunders; 2005.
57. Rossi PG, Parmeggiani A, Posar A, et al. Benign myoclonic epilepsy: long-term follow-up of 11 new cases. Brain Dev. 1997;19:473-479.
58. Claes L, Ceulemans B, Audenaert D, et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum Mutat. 2003;21:615-621.
59. Dravet C. [The behavioral disorders in epilepsy]. Rev Neurol (Paris). 2002;158(5 Pt 2):4S33-4S38.
60. Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol. 2005;95:71-102.
61. Ohmori I, Ouchida M, Ohtsuka Y, et al. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun. 2002;295:17-23.
62. Sugawara T, Mazaki-Miyazaki E, Fukushima K, et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology. 2002;58:1122-1124.
63. Fujiwara T, Sugawara T, Mazaki-Miyazaki E, et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain. 2003;126:531-546.
64. Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS + ? Epilepsia. 2001;42:837-844.
65. Doose H, Lunau H, Castiglione E, et al. Severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures. Neuropediatrics. 1998;29:229-238.
66. Harkin LA, McMahon JM, Iona X, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130(Pt 3):843-852.
67. Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49:45-48.
68. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638-1642.
69. Caraballo RH, Cersosimo RO, Sakr D, et al. Ketogenic diet in patients with Dravet syndrome. Epilepsia. 2005;46:1539-1544.
70. Kang HC, Kim YJ, Kim DW, et al. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilep-sia. 2005;46:272-279.
71. Lagae L. What's new in: "genetics in childhood epilepsy." Eur J Pediatr. 2008;167:715-722.
72. Weber YG, Lerche H. Genetic mechanisms in idiopathic epilepsies. Dev Med Child Neurol. 2008;50:648-654.
73. Lerche H, Weber YG, Baier H, et al. Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. Neurology. 2001;57: 1191-1198.
74. Bonanni P, Malcarne M, Moro F, et al. Generalized epilepsy with febrile seizures plus (GEFS+): clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B, and GABRG2 gene mutations. Epilepsia. 2004;45:149-158.
75. Beaumanoir A, Dravet C. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet C, et al, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey; 1992:115-132.
76. Gastaut H, Roger J, Ouahchi S, et al. An electro-clinical study of generalized epileptic seizures of tonic expression. Epilepsia. 1963;4:15-44.
77. Gastaut H, Roger J, Soulayrol R, et al. [Epileptic encephalopathy of children with diffuse slow spikes and waves (alias "petit mal variant") or Lennox syndrome.] Ann Pediatr (Paris). 1966;13:489-499.
78. Hirsch E, Arzimanoglou A. [Children with drug-resistant partial epilepsy: criteria for the identification of surgical candidates.] Rev Neurol (Paris). 2004;160(Spec No. 1):5S210-5S219.
79. Beaumanoir A. The Lennox-Gastaut syndrome: a personal study. Electro-encephalogr Clin Neurophysiol Suppl. 1982;85-99.
80. Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epi-lepsia. 1997;38:1283-1288.
81. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalop-athy). J Clin Neurophysiol. 2003;20:426-441.
82. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000; 22:75-80.
83. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 2005;20(suppl 1):S1-S56. (Pubitemid 43230877)
84. Ferrie CD, Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). Eur J Paediatr Neurol. 2009;13:493-504.
85. Glauser TA. Topiramate in the catastrophic epilepsies of childhood. J Child Neurol. 2000;15(suppl 1):S14-S21.
86. Hancock EC, Cross HH. Treatment ofLennox-Gastaut syndrome. Cochrane Database Syst Rev. 2003;3:CD003277.
87. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950-1958.
88. Nei M, O'Connor M, Liporace J, et al. Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation. Epilepsia. 2006;47:115-122.
89. Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol. 2001;16:843-848.
90. Freeman JM, Vining EP. Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med. 1999;153:946-949.
91. Velasco AL, Velasco F, Jimenez F, et al. Neuromodulation of the centro-median thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia. 2006;47:1203-1212.
92. Doose H. Myoclonic-astatic epilepsy. Epilepsy Res Suppl. 1992;6:163-168.
93. Dulac O, Plouin P, Shewmon A. Myoclonus and epilepsy in childhood: 1996 Royaumont meeting. Epilepsy Res. 1998;30:91-106.
94. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics. 2002;33: 122-132.
95. Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate. Lancet. 1993;341:445.
96. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol. 2000;15(suppl 1):S7-S13.
97. Doose H, Gerken H, Leonhardt R, et al. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie. 1970;2:59-78.
98. Kramer U, Nevo Y, Neufeld MY, et al. Epidemiology of epilepsy in childhood: a cohort of 440 consecutive patients. Pediatr Neurol. 1998;18: 46-50.
99. Bouma PA, Bovenkerk AC, Westendorp RG, et al. The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta-analysis. Neurology. 1997;48:430-437.
100. Holmes GL. Benign focal epilepsies of childhood. Epilepsia. 1993;34(suppl3):S49-S61.
101. Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 2002;43(suppl 3):27-32.
102. Luders H, Lesser RP, Dinner DS Benign focal epilepsy of childhood. In: Luders H, Leser RP, eds. Epilepsy, Electroclinical Syndromes. Berlin, Germany: Springer, 1987:303-346.
103. Neubauer BA, Fiedler B, Himmelein B, et al. Centrotemporal spikes in families with rolandic epilepsy: linkage to chromosome 15q14. Neurology. 1998;51:1608-1612.
104. Bernardina BD, Sgro V, Fejerman N. Epilepsy with central temporal spikes and related syndromes. In: Roger J, Bureau M, Dravet C, et al, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey; 2002:181-202.
105. Giordani B, Caveney AF, Laughrin D, et al. Cognition and behavior in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsy Res. 2006;70:89-94.
106. Riva D, Vago C, Franceschetti S, et al. Intellectual and language findings and their relationship to EEG characteristics in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. 2007;10:278-285.
107. Kossoff EH, Los JG, Boatman DF. A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy. Epilepsy Behav. 2007;11:514-517.
108. Kavros PM, Clarke T, Strug LJ, et al. Attention impairment in rolandic epilepsy: systematic review. Epilepsia. 2008;49:1570-1580.
109. Perkins FF Jr, Breier J, McManis MH, et al. Benign rolandic epilepsy-perhaps not so benign: use of magnetic source imaging as a predictor of outcome. J Child Neurol. 2008;23:389-393.
110. Fejerman N, Caraballo R, Tenembaum SN. Atypical evolutions of benign localization-related epilepsies in children: are they predictable? Epilepsia. 2000;41:380-390.
111. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120.
112. Coppola G, Franzoni E, Verrotti A, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centro-temporal spikes (BECTS): an open-label, parallel group trial. Brain Dev. 2007;29:281-284.
113. Panayiotopoulos CP. Inhibitory effect of central vision on occipital lobe seizures. Neurology. 1981;31:1330-1333.
114. Kivity S, Ephraim T, Weitz R, et al. Childhood epilepsy with occipital paroxysms: clinical variants in 134 patients. Epilepsia. 2000;41:1522-1533.
115. Panayiotopoulos CP. Vomiting as an ictal manifestation of epileptic seizures and syndromes. J Neurol Neurosurg Psychiatry. 1988;51:1448-1451.
116. Covanis A. Panayiotopoulos syndrome: a benign childhood autonomic epilepsy frequently imitating encephalitis, syncope, migraine, sleep disorder, or gastroenteritis. Pediatrics. 2006;118:1237-1243.
117. Fejerman N. [Benign focal epilepsies in infancy, childhood and adolescence]. Rev Neurol. 2002;34:7-18.
118. Panayiotopoulos CP. Benign childhood epilepsy with occipital paroxysms: a 15-year prospective study. Ann Neurol. 1989;26:51-56.
119. Caraballo R, Cersosimo R, Medina C, et al. Panayiotopoulos-type benign childhood occipital epilepsy: a prospective study. Neurology. 2000;55: 1096-1100.
120. Panayiotopoulos CP, Michael M, Sanders S, et al. Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. Brain. 2008;131:2264-2286.
121. Fejerman N. Benign childhood epilepsy with centrotemporal spikes. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:2369-2377.
122. Ferrie C, Caraballo R, Covanis A, et al. Panayiotopoulos syndrome: a consensus view. Dev Med Child Neurol. 2006;48:236-240.
123. Caraballo RH, Cersosimo RO, Fejerman N. Childhood occipital epilepsy of Gastaut: a study of33 patients. Epilepsia. 2008;49:288-297.
124. Grosso S, Orrico A, Galli L, et al. SCN1A mutation associated with atypical Panayiotopoulos syndrome. Neurology. 2007;69:609-611.
125. Gobbi G, Guerrini R, Grosso S. Late onset childhood occipital epilepsy (Gastaut type). In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:23872395.
126. Smith MC, Hoeppner TJ. Epileptic encephalopathy of late childhood: Landau-Kleffner syndrome and the syndrome of continuous spikes and waves during slow-wave sleep. J Clin Neurophysiol. 2003;20:462-472.
127. McVicar KA Shinnar S. Landau-Kleffner syndrome, electrical status epi-lepticus in slow wave sleep, and language regression in children. Ment Retard Dev Disabil Res Rev. 2004;10:144-149.
128. Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain. 1995;118:1529-1546.
129. Beaumanoir A. The Landau-Kleffner syndrome. In: Roger J, Dravet C, Bureau M, et al, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey; 1985:181-191.
130. Bishop DV. Age of onset and outcome in 'acquired aphasia with convulsive disorder' (Landau-Kleffner syndrome). Dev Med Child Neurol. 1985;27: 705-712.
131. Robinson RO, Baird G, Robinson G, et al. Landau-Kleffner syndrome: course and correlates with outcome. Dev Med Child Neurol. 2001;43:243-247.
132. Tassinari CA, Michelucci R, Forti A, et al. The electrical status epilepticus syndrome. Epilepsy Res Suppl. 1992;6:111-115.
133. Tassinari CA, Rubboli G, Volpi L, et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia [review]. Clin Neurophysiol. 2000;111(suppl 2):S94-S102.
134. Debiais S, Tuller L, Barthez MA, et al. Epilepsy and language development: the continuous spike-waves during slow sleep syndrome. Epilepsia. 2007; 48:1104-1110.
135. Bureau M. Continuous spikes and waves during slow sleep (CSWS): definition of the syndrome. In: Beaumanoir A, Bureau M, Deonna T, et al, eds. Continuous Spikes and Waves During Slow Sleep: Electrical Status Epilepticus During Slow Sleep. London: John Libbey; 1995;17-26.
136. Kawakami Y, Matsumoto Y, Hashimoto K, et al. Treatment with flunitraz-epam of continuous spikes and waves during slow wave sleep (CSWS) in children. Seizure. 2007;16:190-192.
137. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol. 1991;33:257-260.
138. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neuro-surg Psychiatry. 1996;61:433-443.
139. Maljevic S, Krampfl K, Cobilanschi J, et al. A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy. Ann Neurol. 2006;59:983-987.
140. Blumenfeld H. Cellular and network mechanisms of spike-wave seizures. Epilepsia. 2005;46(suppl 9):21-33.
141. Chan CH, Briellmann RS, Pell GS, et al. Thalamic atrophy in childhood absence epilepsy. Epilepsia. 2006;47:399-405.
142. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New Engl JMed. 2010;362:790-799.
143. Pavone P, Bianchini R, Trifiletti RR, et al. Neuropsychological assessment in children with absence epilepsy. Neurology. 2001;56:1047-1051.
144. Wirrell EC, Camfield CS, Camfield PR, et al. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology. 1996;47:912-918.
145. Tovia E, Goldberg-Stern H, Shahar E, et al. Outcome of children with juvenile absence epilepsy. J Child Neurol. 2006;21:766-768.
146. Zifkin B, Andermann E, Andermann F. Mechanisms, genetics, and patho-genesis of juvenile myoclonic epilepsy. Curr Opin Neurol. 2005;18:147-153.
147. Mullins GM, O'Sullivan S S, Neligan A, et al. A study of idiopathic generalised epilepsy in an Irish population. Seizure. 2007;16:204-210.
148. Cossette P, Liu L, Brisebois K, et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet. 2002;31:184-189.
149. Haug K, Warnstedt M, Alekov AK, et al. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet. 2003;33:527-532.
150. Camfield C, Camfield P. Management guidelines for children with idio-pathic generalized epilepsy. Epilepsia. 2005;46(suppl 9):112-116.
151. Genton P, Roger J, Guerrini R, et al. History and classification of "myo-clonic" epilepsies: from seizures to syndromes to diseases. Adv Neurol. 2005;95:1-14.
152. Berkovic SF. Progressive myoclonic epilepsies. In: Engel J, Pedley TA, eds. Epilepsy: AComprehensive Textbook, Philadelphia PA: Lippincott-Raven; 1997:2455-2468.
153. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005;4:239-248.
154. Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008;10:31-34.
155. Conry JA. Progressive myoclonic epilepsies. J Child Neurol. 2002;17(suppl 1):S80-S84.
156. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005; 128(Pt 3):454-471.
157. Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology. 1958;8:435-445.
158. Pardo CA, Vining EP, Guo L, et al. The pathology ofRasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia. 2004;45:516-526.
159. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology. 2003;61:1807-1810.
160. Kossoff EH, Vining EP, Pillas DJ, et al. Hemispherectomy for intractable unihemispheric epilepsy etiology vs outcome. Neurology. 2003;61:887-890.
161. Pulsifer MB, Brandt J, Salorio CF, et al. The cognitive outcome of hemispherectomy in 71 children. Epilepsia. 2004;45:243-254.